Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug;4(3):223-30.
doi: 10.2174/157340308785160598.

Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention

Hideki Ishii  1 , Tetsuya Amano, Tatsuaki Matsubara, Toyoaki Murohara
Affiliations

Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention

Hideki Ishii et al. Curr Cardiol Rev. 2008 Aug.

Abstract

In recent years, percutaneous coronary intervention (PCI) has become a well-established technique for the treatment of coronary artery disease. PCI improves symptoms in patients with coronary artery disease and it has been increasing safety of procedures. However, peri- and post-procedural myocardial injury, including angiographical slow coronary flow, microvascular embolization, and elevated levels of cardiac enzyme, such as creatine kinase and troponin-T and -I, has also been reported even in elective cases. Furthermore, myocardial reperfusion injury at the beginning of myocardial reperfusion, which causes tissue damage and cardiac dysfunction, may occur in cases of acute coronary syndrome. Because patients with myocardial injury is related to larger myocardial infarction and have a worse long-term prognosis than those without myocardial injury, it is important to prevent myocardial injury during and/or after PCI in patients with coronary artery disease. To date, many studies have demonstrated that adjunctive pharmacological treatment suppresses myocardial injury and increases coronary blood flow during PCI procedures. In this review, we highlight the usefulness of pharmacological treatment in combination with PCI in attenuating myocardial injury in patients with coronary artery disease.

Keywords: Coronary artery disease; myocardial injury; percutaneous coronary intervention; pharmacology..

PubMed Disclaimer

References

    1. Ravkilde J, Nissen H, Mickley H, Andersen PE, Thayssen P, Horder M. Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. Am Heart J. 1994;127:13–20. - PubMed
    1. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241–51. - PubMed
    1. Ohman EM, Tradiff BE. Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization: importance and implications. JAMA. 1997;277:495–7. - PubMed
    1. Simonton CA, Leon MB, Baim DS, et al. ‘Optimal’ directional coronary atherectomy: final results of the Optimal Atherectomy Restenosis Study (OARS) Circulation. 1998;97:332–9. - PubMed
    1. Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponon-I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077–82. - PubMed